Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.
about
Parainfluenza virusesSpecific and nonspecific obstructive lung disease in childhood: causes of changes in the prevalence of asthma.Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to activate ERK1 and ERK2.Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice.Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challengePrimary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.Development of interleukin 6 and tumor necrosis factor alpha activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus.Progress in understanding and controlling respiratory syncytial virus: still crazy after all these yearsAntigenic Fingerprinting following Primary RSV Infection in Young Children Identifies Novel Antigenic Sites and Reveals Unlinked Evolution of Human Antibody Repertoires to Fusion and Attachment Glycoproteins.Development of Acquired Immunity following Repeated Respiratory Syncytial Virus Infections in Cotton Rats.The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and diseaseInability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responsesDetection, pathogenesis, and therapy of respiratory syncytial virus infectionsIdentifying infections with respiratory syncytial virus by using specific immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral-fluid samples.Live-attenuated respiratory syncytial virus vaccines.Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation.Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity.Respiratory syncytial virus group-specific antibody response in nasopharyngeal secretions from infants and children after primary infectionAntibody response to respiratory syncytial virus infection in children <18 months oldFormalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.Serum immunoglobulin G antibody subclass response to respiratory syncytial virus F and G glycoproteins after first, second, and third infections.Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.Serum immunoglobulin G antibody subclass responses to respiratory syncytial virus F and G glycoproteins after primary infection.Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.Serodiagnosis of respiratory syncytial virus (RSV) infection in children as measured by detection of RSV-specific immunoglobulins G, M, and A with enzyme-linked immunosorbent assayThe Human Immune Response to Respiratory Syncytial Virus Infection.Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies.Detection of antibodies to respiratory syncytial virus attachment and nucleocapsid proteins with recombinant baculovirus-expressed antigensRespiratory syncytial virus-specific antibody responses in immunoglobulin A and E isotypes to the F and G proteins and to intact virus after natural infection.Monoclonal antibody-based capture enzyme immunoassays for specific serum immunoglobulin G (IgG), IgA, and IgM antibodies to respiratory syncytial virus.Antibody-dependent enhancement of respiratory syncytial virus infection by sera from young infants.Why do viruses make infants wheeze?The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations.Kinetics of the neutralizing antibody response to respiratory syncytial virus infections in a birth cohortRespiratory syncytial virus and the infant immune response.
P2860
Q24682952-FBCF2CD3-E6FD-493E-B8A9-230EB30D0006Q30305925-74A0EBD2-6F64-429A-BCC8-9727393D64D4Q30425776-12AA777B-53F7-44C7-A67C-3F84A7072F4BQ33725040-7D4F8ECE-61C3-4E19-8A9E-440E75C67F2CQ33783066-CFBED769-1E6B-4362-A62F-4EC6DB7E97D6Q33813095-28199C07-48A7-487C-AB97-5B9E035860A7Q33815412-00794F5B-5F28-4C45-BF8D-DF372664E33CQ34307704-6D4D3C6B-15DD-4608-A754-38668798FE3CQ35102554-A90B7538-8F9B-4C6D-9B24-C7458660B7DFQ35224466-D390AD20-2158-4F31-B0DB-18B951C50F16Q35566601-2499D828-FAEF-40E3-B42F-23E4289F9D36Q35995788-15493D46-7199-4521-BD1E-50DC62EA64B5Q36029171-C432B5A1-F9E8-4ADA-8BB1-9B346461614FQ36347623-49E54481-CF4E-4AA5-9D36-4D3A3A88FA4BQ36539394-CAA7C216-AFC0-44EB-9CF7-D7C847FE774CQ36632499-2B321BE0-28ED-4B82-A1F5-6C04AD387461Q36673041-B92B62E7-BD20-4B9D-9A37-DB5B75295D30Q36692801-E87D1AC2-B43E-4A84-9AF5-A000FA94B052Q36831654-C756DF2C-DE22-4B33-87BB-2929DBC5FD3CQ36873249-BB3A88E3-2138-44C1-AB70-67AA2D3AF7F0Q36919232-9D1AB88D-B101-434E-BCA6-28E92DDA55E6Q36930001-56AAAC43-C332-4B6E-AA75-D24F65A494A1Q37135395-D23D99FE-E691-4E76-A9AA-9A98AF73D3FEQ37153108-5F280795-9516-415B-A878-1933C75649FAQ37170484-79223DDA-7C0D-4EBF-BE1C-EF07F2553C5BQ37208256-6CCC7D21-8A2E-4271-83B8-776F052AA26AQ37208820-BAA3D8B1-FAAA-4E36-889B-A61F6510E0C3Q37212728-FEC13629-7302-405B-88E5-D5FFCA5F4349Q37225472-FF34B063-E586-4011-A4CE-C1BF8EBDDDADQ39127064-2CF14A03-D4ED-4782-80AB-279263D8E3DDQ39810460-A5CEFFC8-FFC3-4BAD-A55B-BEAA1BBD3494Q40012955-4CD059C5-E387-4201-A4DC-09E33A3BF999Q40198510-1A279E5F-FB58-422F-94E9-2569E7BA0939Q40203367-5487D85E-EA49-4E11-BA6E-A1A0D06CB9C1Q40673105-9202784F-EED2-4636-830D-4843DE15220FQ41096329-5B15D4BE-C527-42CB-BE4A-D152E48279E4Q41829277-7775FDB6-4C44-4593-BB82-57E4146D4544Q41875572-78153DA1-78AF-432E-8A9F-EB9C3F4EC965Q42068741-B5931355-F4A4-4345-B587-BA319F3CD741
P2860
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1986
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum and nasal-wash immunoglo ...... s following primary infection.
@en
Serum and nasal-wash immunoglo ...... s following primary infection.
@nl
type
label
Serum and nasal-wash immunoglo ...... s following primary infection.
@en
Serum and nasal-wash immunoglo ...... s following primary infection.
@nl
prefLabel
Serum and nasal-wash immunoglo ...... s following primary infection.
@en
Serum and nasal-wash immunoglo ...... s following primary infection.
@nl
P2093
P2860
P1476
Serum and nasal-wash immunoglo ...... ns following primary infection
@en
P2093
B R Murphy
B S Graham
D T Karzon
G A Prince
P F Wright
R M Chanock
P2860
P304
P407
P577
1986-06-01T00:00:00Z